Comprehensive List of PGx Information in Current US Drug Labeling

The US Food and Drug Administration plays an important role in acknowledging current medications whose effectiveness is directly related to individuals' genetic information and carries the additional responsibility of ensuring the public is made fully aware of drugs on the market that carry these particular risks.

An example of the utility of the comprehensive list linked below is Clopidogrel (Plavix):

 The FDA has included a black box warning on Clopidogrel (Plavix) for those who are intermediate and poor metabolizers as an effort to reduce the advent of adverse drug reactions.  

The FDA has included a black box warning on Clopidogrel (Plavix) for those who are intermediate and poor metabolizers as an effort to reduce the advent of adverse drug reactions.  

Please visit the FDA-hosted table below for all PGx-related information concerning today's medications. 

READ MORE HERE